• 1. Effect of puckering motion and hydrogen bond formation on the vibrational circular dichroism spectrum of a flexible molecule: the case of (S)-1-indanol
  Katia Le Barbu-Debus,Arne Scherrer,Aude Bouchet,Daniel Sebastiani,Rodolphe Vuilleumier,Anne Zehnacker Phys. Chem. Chem. Phys. 2018 20 14635
• 2. Chirality-dependent balance between hydrogen bonding and London dispersion in isolated (±)-1-indanol clusters
  Jonas Altn?der,Aude Bouchet,Juhyon J. Lee,Katharina E. Otto,Martin A. Suhm,Anne Zehnacker-Rentien Phys. Chem. Chem. Phys. 2013 15 10167
• 3. γ-Sultam-cored N,N-ligands in the ruthenium(ii)-catalyzed asymmetric transfer hydrogenation of aryl ketones
  Slavko Rast,Barbara Modec,Michel Stephan,Barbara Mohar Org. Biomol. Chem. 2016 14 2112
• 4. Benzocycloarene hydroxylation by P450 biocatalysis
  Martin P. Mayhew,Adrian E. Roitberg,Yadu Tewari,Marcia J. Holden,David J. Vanderah,Vincent L. Vilker New J. Chem. 2002 26 35
• 5. Biotransformations
  Gideon Grogan Annu. Rep. Prog. Chem. Sect. B: Org. Chem. 2010 106 216

• Solvents and Organic Chemicals Organic Compounds Benzenoids Indanes Indanes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Indanes

Recent Advances in the Application of (1R)-indan-1-ol (CAS 697-64-3) in Chemical Biology and Pharmaceutical Research

The chiral alcohol (1R)-indan-1-ol (CAS 697-64-3) has recently emerged as a valuable building block in pharmaceutical synthesis and chemical biology research. This compound, characterized by its indane scaffold with a stereocenter at the 1-position, has demonstrated significant potential in the development of novel therapeutic agents and chemical probes. Recent studies have highlighted its utility as a precursor for various biologically active molecules, particularly in the fields of neurology and oncology.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient synthesis of (1R)-indan-1-ol derivatives as potent inhibitors of monoamine oxidase B (MAO-B), showing promising results in Parkinson's disease models. The researchers employed an asymmetric hydrogenation approach to achieve high enantiomeric purity (>99% ee) of the starting material, which proved crucial for biological activity. This work builds upon previous findings that established the importance of the (R)-configuration for MAO-B inhibition.

In the field of oncology, a recent patent application (WO2023056421) disclosed novel (1R)-indan-1-ol-containing compounds as selective estrogen receptor degraders (SERDs) for breast cancer treatment. The indanol moiety was found to significantly enhance the metabolic stability of these compounds while maintaining their therapeutic efficacy. Molecular modeling studies revealed that the specific spatial orientation of the hydroxyl group in (1R)-indan-1-ol contributes to optimal receptor binding.

From a synthetic chemistry perspective, significant progress has been made in the catalytic asymmetric synthesis of (1R)-indan-1-ol. A 2024 report in ACS Catalysis described a novel biocatalytic route using engineered alcohol dehydrogenases that achieved quantitative yields with perfect stereoselectivity. This green chemistry approach addresses previous challenges in the large-scale production of enantiomerically pure (1R)-indan-1-ol, potentially lowering production costs for pharmaceutical applications.

The compound's unique physicochemical properties have also been exploited in chemical biology applications. Researchers at several institutions have recently developed (1R)-indan-1-ol-based fluorescent probes for studying lipid membranes (Nature Chemical Biology, 2023). The rigid indane scaffold provides excellent photostability, while the hydroxyl group allows for specific membrane localization. These probes have enabled real-time visualization of membrane dynamics in live cells with unprecedented resolution.

Looking forward, the versatility of (1R)-indan-1-ol suggests it will continue to play an important role in drug discovery and chemical biology. Current research directions include its incorporation into PROTAC molecules (proteolysis targeting chimeras) and as a chiral auxiliary in asymmetric synthesis. The compound's favorable ADME properties and demonstrated biological activities make it particularly attractive for further pharmaceutical development. Future studies are expected to explore additional therapeutic applications and more efficient synthetic routes for this valuable chiral building block.

• 32521-03-2(5,6-Dimethyl-1-indanol)
• 36643-74-0(1H-Indenol,2,3-dihydro-)
• 200425-63-4(6-Methyl-2,3-dihydro-1H-inden-1-ol)
• 67864-03-3(4-Methyl-2,3-dihydro-1H-inden-1-ol)
• 923977-20-2(5,7-Dibutyl-2,3-dihydro-1H-inden-1-ol)
• 944-42-3( )
• 494867-40-2(1H-Inden-1-ol, 2,3-dihydro-, (1R)-, compd. with (2S)-2-hexanol (1:1))
• 33781-37-2(5-Methyl-2,3-dihydro-1H-inden-1-ol)
• 25501-32-0((1S)-indan-1-ol)
• 6351-10-6(1-Indanol)